Retatrutide Phase 3 Results 2026: TRIUMPH-4 Decoded

What retatrutide is (mechanism)

Retatrutide (development code LY3437943) is an investigational synthetic peptide developed by Eli Lilly. It engages three metabolic receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. The triple-agonism approach extends the receptor-engagement strategy that semaglutide (GLP-1 mono-agonism) and tirzepatide (GIP/GLP-1 dual agonism) introduced. Retatrutide is investigational and NOT FDA-approved as of May 2026.

Why three receptors instead of one or two

Each receptor contributes a different metabolic effect. GLP-1 receptor agonism enhances glucose-dependent insulin secretion, suppresses glucagon under fed conditions, slows gastric emptying, and reduces appetite through central pathways. GIP receptor agonism augments insulin secretion in fed states and may modulate lipid metabolism and tolerability. Glucagon receptor agonism, counterintuitive in a weight-loss context, is thought to increase energy expenditure (resting metabolic rate) — a different mechanism of action than reducing intake alone. The proposed clinical hypothesis is that adding glucagon receptor engagement layers an energy-expenditure effect onto the appetite-and-incretin effects of GLP-1 and GIP. Retatrutide remains investigational and NOT FDA-approved.

The plain-English summary: semaglutide reduces appetite via one receptor; tirzepatide reduces appetite and modulates lipid handling via two receptors; retatrutide adds a third receptor that targets energy expenditure. The Phase 3 results will tell us whether the mechanistic hypothesis translates into real-world clinical practice — pending FDA review.

The TRIUMPH Phase 3 trial program

Eli Lilly's TRIUMPH program is the Phase 3 trial set evaluating retatrutide across multiple patient populations. The named trials include TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, and TRIUMPH-4, with additional trials evaluating retatrutide in specific comorbid populations (sleep apnea, knee osteoarthritis, cardiovascular outcomes). The TRIUMPH naming convention parallels Novo Nordisk's STEP program for semaglutide and Eli Lilly's SURMOUNT program for tirzepatide. Trial designs typically include randomization to placebo or retatrutide at multiple doses, with primary endpoints of mean body weight reduction over a defined treatment duration (typically 48-72 weeks). None of these trials have produced FDA-approved consumer access; retatrutide remains investigational and NOT FDA-approved.

TRIUMPH-4 results in detail (2026 readout)

The TRIUMPH-4 Phase 3 trial focused on adults with obesity and concurrent knee osteoarthritis pain, allowing the trial to capture both weight-related and joint-pain endpoints. The 2026 readout reported:

• Mean body weight reduction: Approximately 28.7 percent at the highest retatrutide dose tested, versus a placebo arm with the expected minimal placebo response. This is the largest mean body weight reduction reported for any GLP-1 family agent to date in a Phase 3 trial population.
• Knee osteoarthritis pain reduction: Approximately 75.8 percent improvement in the WOMAC pain subscale at the highest dose, versus placebo. WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) is a validated patient-reported outcome measure for hip and knee osteoarthritis.
• Sample size and duration: Several hundred adults randomized across multiple dose arms over the trial treatment period.
• Adverse events: Gastrointestinal events were the dominant adverse event class, dose-dependent, consistent with the GLP-1 receptor agonist family pattern. Full Phase 3 adverse event profiling is ongoing through the regulatory review process.

These are trial outcomes from a controlled clinical research population, not consumer outcomes and not a guarantee of individual response. Mean reductions in randomized controlled trials are population-level statistics; individual response varies significantly. The trial population met specific inclusion criteria that may not match the general consumer population. Retatrutide is investigational and NOT FDA-approved.

Phase 2 context — NEJM 2023

The retatrutide Phase 2 trial published in the New England Journal of Medicine in 2023 (PMID 37296141) provided the foundational efficacy and safety data that motivated the Phase 3 TRIUMPH program. Key details:

• Population: 338 adults with obesity, BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity.
• Design: Randomized, double-blind, placebo-controlled, multiple dose escalation arms.
• Duration: 48 weeks of treatment.
• Primary outcome: Mean body weight reduction approached approximately 24 percent at the highest dose, versus minimal placebo response.
• Safety: Adverse events were predominantly gastrointestinal, dose-dependent, consistent with the broader GLP-1 receptor agonist class. Most events were mild to moderate, with a small fraction leading to dose reduction or discontinuation.

The Phase 2 data anchored the mechanistic and efficacy hypothesis. The Phase 3 TRIUMPH program is the larger-population confirmation that will inform the eventual FDA review. Retatrutide remains investigational and NOT FDA-approved as of May 2026.

How retatrutide compares to approved GLP-1s (mechanism only, with caveat)

The mechanistic comparison is the most-asked question and the most easily misread. Mean body weight reductions across trials should be read as trial outcomes in different populations and trial designs, not as a direct clinical comparison.

The gradient from semaglutide to tirzepatide to retatrutide is approximately what the mechanistic hypothesis predicted: adding receptor engagement adds efficacy, up to a point. But cross-trial comparison is not a substitute for a head-to-head trial. Trial populations, durations, dose-titration schedules, and placebo responses differ. No randomized head-to-head trial of retatrutide versus tirzepatide or semaglutide has been published.

Retatrutide is investigational and NOT FDA-approved. Comparison to approved drugs is a mechanistic and trial-population statement, not a clinical recommendation. For the head-to-head among currently approved options see our semaglutide vs tirzepatide comparison.

When will retatrutide be FDA-approved?

We will not speculate on a specific availability date. The FDA approval process depends on the complete Phase 3 data package across multiple TRIUMPH trials, the sponsor's New Drug Application submission, FDA review timelines (typically 10-12 months for standard review, 6 months for priority review), and any regulatory questions raised during the review process. Public industry estimates have ranged from late 2026 to 2028, but these are estimates from analysts and trade publications, not FDA announcements or Eli Lilly committed timelines.

What we can say with confidence:

• Retatrutide is investigational and NOT FDA-approved as of May 2026.
• FDA review is contingent on a New Drug Application submission, which requires the full Phase 3 data package.
• No legal pathway exists for US consumers to obtain retatrutide outside an active enrolled clinical trial.
• The retatrutide approval timeline is set by trial completion, sponsor submission, and FDA review — not by social-media speculation or telehealth-provider marketing claims.

For the current FDA tracker view, see our retatrutide approval tracker. For waitlist notification when status changes, the retatrutide waitlist is how we notify subscribers.

What retatrutide is NOT (critical compliance section)

NOT FDA-approved

Retatrutide is investigational and NOT FDA-approved as of May 2026. No FDA-approved finished product exists. No prescribing information exists. No FDA-approved indication exists.

NOT legally available outside a clinical trial

The only legal pathway to receive retatrutide in the United States is enrollment in an active TRIUMPH or related clinical trial registered on ClinicalTrials.gov. Trials have specific eligibility criteria and enrollment availability changes over time. No telehealth provider, no compounding pharmacy, no online seller, no research-peptide supplier can lawfully provide retatrutide for human use.

NOT compoundable under 503A or 503B

US compounding pharmacies cannot lawfully compound retatrutide. The 503A framework requires a clinical-need justification anchored to an FDA-approved reference product; the 503B framework requires inclusion on the Bulks List or a similar regulatory basis. Retatrutide has neither — it is investigational. Any compounding pharmacy advertising "compounded retatrutide" is operating outside the legitimate compounding framework, regardless of how the marketing copy frames it.

Red flags if a provider claims to offer retatrutide in 2026

The following claims, taken individually or together, are red flags for an illegitimate operator:

• "Compounded retatrutide available through licensed 503A pharmacy" — false. Not lawfully compoundable.
• "FDA-approved retatrutide" — false. Retatrutide is NOT FDA-approved.
• "Research peptide retatrutide for personal use" — outside the pharmacy regulatory framework. Not regulated. Not safe.
• "Get retatrutide before everyone else" — manufactured urgency around an unapproved drug.
• "Compounded combination including retatrutide" — same issue. Retatrutide cannot be lawfully compounded.
• "Imported retatrutide from overseas" — unregulated import. Not legal for personal use in the United States.

Our editorial position: we do not endorse any provider claiming retatrutide access in 2026. If a current GLP-1 telehealth provider you trust starts advertising retatrutide, that should reduce, not increase, your confidence in their other claims. The legitimate operators wait for approval like everyone else.

Safety considerations from current data

What the published evidence shows about retatrutide safety, with the major caveat that Phase 3 safety profiling is still being completed and the eventual FDA-approved prescribing information will be the authoritative source:

• Gastrointestinal: Nausea, vomiting, diarrhea, constipation, abdominal discomfort were the most common adverse events in Phase 2 (PMID 37296141), dose-dependent, consistent with the broader GLP-1 receptor agonist class.
• Heart rate: Mild increases in resting heart rate have been observed across the GLP-1 family. Detailed cardiovascular monitoring is part of the Phase 3 program.
• Pancreatitis, gallbladder events: Documented risks across the GLP-1 family; final retatrutide-specific labeling will reflect Phase 3 findings.
• Thyroid C-cell tumors: Boxed warning across the approved GLP-1 family based on rodent studies; retatrutide labeling on approval will reflect FDA review.
• Long-term safety: Not yet established beyond the trial period. Post-marketing surveillance after approval will be the primary source of long-term safety signal.

The honest answer to "is retatrutide safer than tirzepatide or semaglutide" is: we cannot say yet. Comparative safety claims require head-to-head trials and post-marketing surveillance that does not yet exist for retatrutide. Retatrutide is investigational and NOT FDA-approved.

What to do if you are waiting on approval

If retatrutide is on your radar because of the Phase 3 data, the realistic options are limited and depend on what your priority is.

Option 1 — Join the approval waitlist

The retatrutide approval waitlist notifies subscribers when FDA approval status changes. Free, no commitment, no provider link. This is how we recommend tracking the regulatory timeline. Retatrutide remains investigational and NOT FDA-approved.

Option 2 — Explore clinical trial enrollment

ClinicalTrials.gov is the federally maintained registry of active clinical trials. Search "retatrutide" or "LY3437943" for current TRIUMPH or related trials. Eligibility criteria vary; enrollment changes as trials reach sample size and close enrollment. Contact listed trial sites directly to inquire. This is the only legal pathway to receive retatrutide in the US.

Option 3 — Start an FDA-approved alternative now

Semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved with substantial published efficacy and known safety profiles. Compounded semaglutide and compounded tirzepatide are accessible through 503A telehealth providers under defined conditions. Waiting indefinitely for an investigational drug with an unknown approval date may not be the best clinical choice for everyone. For approved options, see our best telehealth for weight loss 2026 rankings or the semaglutide vs tirzepatide comparison. (Affiliate links — see disclosure.)

Option 4 — Do NOT buy gray-market retatrutide

The "compounded retatrutide" and "research peptide retatrutide" markets do exist online. They are not legal, not regulated, and not safe. Buying from these channels means no prescriber oversight, no third-party Certificates of Analysis from recognized labs, frequent contamination in independent testing, and no recourse if injury occurs. The first-mover-advantage framing some sellers use is a marketing trick, not a clinical reality. Retatrutide is investigational and NOT FDA-approved.

Frequently asked questions

Bottom line and next steps

Retatrutide's TRIUMPH-4 Phase 3 readout of approximately 28.7 percent mean body weight reduction is the largest reported in the GLP-1 family pivotal-trial literature to date. The mechanism — adding glucagon receptor agonism to the GIP and GLP-1 engagement of tirzepatide — is mechanistically interesting and likely explains the trial efficacy gradient. Retatrutide is investigational and NOT FDA-approved as of May 2026. There is no legal pathway to receive retatrutide outside an active clinical trial, and operators claiming otherwise are outside the legitimate framework.

If retatrutide is on your radar:

• Join the retatrutide approval waitlist for notification when FDA status changes.
• Track regulatory progress via the retatrutide approval tracker.
• Explore active clinical trials via ClinicalTrials.gov (search "retatrutide" or "LY3437943").
• If you need an FDA-approved option now, compare verified providers in best telehealth for weight loss 2026 or read the semaglutide vs tirzepatide comparison.
• For the regulatory framework around compounded GLP-1s, see is compounded semaglutide legal in 2026.
• For the head-to-head we cannot yet do (retatrutide vs tirzepatide), see our retatrutide vs tirzepatide explainer.

We do not endorse any provider claiming retatrutide access in 2026. Anyone claiming otherwise is selling something other than retatrutide, or selling outside the regulated pharmacy and clinical-trial framework. Talk to a licensed physician familiar with your medical history before making decisions about GLP-1 therapy, approved or investigational.

Sources & clinical references

1. [1] Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37296141
2. [2] Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
3. [3] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID: 35658024
4. [4] Eli Lilly and Company. TRIUMPH Phase 3 clinical trial program — TRIUMPH-1, -2, -3, -4 registry entries. ClinicalTrials.gov public registry.
5. [5] U.S. Food & Drug Administration. Investigational New Drug regulatory framework. 21 CFR 312.
6. [6] U.S. Food & Drug Administration. Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Drug Quality and Security Act (DQSA), Public Law 113-54 (2013).
7. [7] Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) — validated patient-reported outcome measure.

Disclaimers

RETATRUTIDE STATUS: Retatrutide is investigational and NOT FDA-approved as of May 2026. No legal pathway exists for US consumers to obtain retatrutide outside an active enrolled clinical trial. We do not endorse any provider claiming retatrutide access in 2026.

FTC Affiliate Disclosure: This article does not contain affiliate links to retatrutide providers — no legitimate retatrutide provider exists. Links to FDA-approved GLP-1 alternatives elsewhere on the site may be affiliate links generating commission at no additional cost to you. Editorial assessment is independent.

Educational Disclaimer: This article is for educational purposes only and is not medical advice. Trial outcomes are population-level statistics, not consumer outcomes or guarantees of individual response. Phase 3 safety data is still being collected. The eventual FDA-approved prescribing information will be the authoritative source on retatrutide if and when approval occurs. Always consult a licensed healthcare provider before making decisions about GLP-1 therapy, approved or investigational.